CD4 and neoplasm: In the present study, one patient who received PF-04136309 had an increase in programmed cell death protein 1 (PD-1) + CD4+ and PD-1 + CD8+ cells in the tumor biopsy sample (data not shown), suggesting PF-04136309 also modulated PD-1 immune checkpoint in mPDAC.